Interim evaluation of efficacy or futility in group‐sequential trials with multiple co‐primary endpoints
DOI10.1002/BIMJ.201600026zbMATH Open1369.62288OpenAlexW2532695412WikidataQ39272947 ScholiaQ39272947MaRDI QIDQ5280188FDOQ5280188
Authors: Koko Asakura, Toshimitsu Hamasaki, Scott R. Evans 
Publication date: 20 July 2017
Published in: Biometrical Journal (Search for Journal in Brave)
Full work available at URL: http://europepmc.org/articles/pmc6222168
Recommendations
- Group-Sequential Clinical Trials with Multiple Co-Objectives
- Design and Analysis of Group Sequential Clinical Trials with Multiple Primary Endpoints
- Interim and terminal analyses of clinical trials with failure-time endpoints and related group sequential designs
- Evaluating co-primary endpoints collectively in clinical trials
- A New Interim Monitoring Statistic for Group Sequential Clinical Trials
- Interim analyses with repeated measurements in a sequential clinical trial
- A gatekeeping procedure to test a primary and a secondary endpoint in a group sequential design with multiple interim looks
futilitygroup sequential designmultiple endpointserror-spending methodnonbinding boundarytype I and type II error adjustments
Applications of statistics to biology and medical sciences; meta analysis (62P10) Optimal statistical designs (62K05) Sequential statistical analysis (62L10)
Cites Work
- Title not available (Why is that?)
- Discrete Sequential Boundaries for Clinical Trials
- Design and Analysis of Group Sequential Clinical Trials with Multiple Primary Endpoints
- Testing a Primary and a Secondary Endpoint in a Group Sequential Design
- Group Sequential Tests for Bivariate Response: Interim Analyses of Clinical Trials with Both Efficacy and Safety Endpoints
- Closed Testing Procedures for Group Sequential Clinical Trials with Multiple Endpoints
- Guidelines for Monitoring Efficacy and Toxicity Responses in Clinical Trials
- Symmetric Group Sequential Test Designs
- Stochastically curtailed tests in long–term clinical trials
- Sample size determination in clinical trials with multiple endpoints
- Title not available (Why is that?)
- Group-Sequential Clinical Trials with Multiple Co-Objectives
Cited In (8)
- A new approach for sizing trials with composite binary endpoints using anticipated marginal values and accounting for the correlation between components
- Group-Sequential Clinical Trials with Multiple Co-Objectives
- Group sequential designs for clinical trials with bivariate endpoints
- Group sequential two-stage preference designs
- Evaluating co-primary endpoints collectively in clinical trials
- Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables
- Simultaneous population enrichment and endpoint selection in phase 3 randomized controlled trials: An adaptive group sequential design with two binary alternative primary endpoints
- Adaptive group-sequential design with population enrichment in phase 3 randomized controlled trials with two binary co-primary endpoints
Uses Software
This page was built for publication: Interim evaluation of efficacy or futility in group‐sequential trials with multiple co‐primary endpoints
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5280188)
